Biotech Values

[cooldrinkh2o]

Inclusig will likely be second line if pt fails tasigna


The DC rates for the ABLs are close to 20% and the AE profiles are different enough that I think Iclusig will still get use. The uptake curve, however, will likely become more shallow - closer to the original nilotinib uptake curve.